Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts. Show more

Location: 131 Dartmouth Street, Boston, MA, 02116, United States | Website: https://www.adicetbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

61.99M

52 Wk Range

$0.45 - $1.70

Previous Close

$0.74

Open

$0.72

Volume

481,609

Day Range

$0.71 - $0.76

Enterprise Value

-83.74M

Cash

150.4M

Avg Qtr Burn

-23.73M

Insider Ownership

2.81%

Institutional Own.

67.37%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.